Front Genome Ed
These include organ- and tissue-protective actions on the kidneys, bones, nervous system, heart, brain, liver, lungs, uterus, ovaries, and more, alongside notable anti-arthritis, anti-cancer, and anti-diabetic properties
Phase 1b PoC fully enrolled APG273APG273 / IL-13 + TSLP / combination of zumilokibart (APG777) + APG333 monoclonal antibodies / respiratory immunology and inflammationAsthma / COPDPreclinicalin-progress APG808APG808 / IL-4R / antibody / respiratory immunology and inflammationAsthmaPhase 1bpositive interim results announced May 2025 4assets BPL-003BPL-003 / Intranasal mebufotenin benzoate / Mental healthTreatment-resistant depressionPhase 2In development VLS-01VLS-01 / 5-HT1/2/6/7 receptor agonist / Oral transmucosal DMT buccal film / Mental healthTreatment-resistant depressionPhase 2In development EMP-01EMP-01 / Oral R-MDMA / Mental healthSocial anxiety disorderPhase 2Positive topline results announced Novel 5-HT2A Receptor Agonists5-HT2A receptor / Small-molecule neuroplastogens / Mental healthOpioid use disorderDiscoveryIn developmentTreatment-resistant depressionDiscoveryIn development 4assets DeramiocelCAP-1002 / allogeneic CDCs / Neuromuscular diseaseDuchenne muscular dystrophy (DMD)Phase 3in progressBecker muscular dystrophy (BMD)Preclinicalin progress StealthXSTX-S / Exosome-based vaccine / Infectious diseaseSARS-CoV-2Phase 1in progress StealthXTherapeutic ExosomesEvaluatingPreclinicalin progress CDC-ExosomesExosome Platform / Neuromuscular diseaseDuchenne muscular dystrophyPreclinicalin progress 4assets CLN-978CLN-978 / CD19xCD3 / bispecific T cell engager / ImmunologyOUTRACE: Rheumatoid arthritisPhase 1Initial data in RA in Q2 2026 and repeat dosing data in Q3 2026EuropeOUTRACE: Systemic lupus erythematosusPhase 1bInitial data in SLE in Q2 2026GlobalOUTRACE: Sjgrens diseasePhase 1Initial data in Sjgrens disease in Q4 2026Global VelinotamigBCMAxCD3 / bispecific T cell engager / ImmunologyAutoimmune diseasesIND-EnablingGenrix Bio initiated a Phase 1 study in China in Q4 2025
2025 Case Report This case report followed a 23-year-old obese female who had been using semaglutide for weight loss over the prior 4 months, injecting 0.25 mg once weekly for the first 2 months, and 0.5 mg once weekly for the remaining 2 months
Maintaining losses requires ongoing attention to diet, exercise, and potentially continued medication
